), a carbonic anhydrase inhibitor, which has been conventionally used as a component of eye drops, and timolol maleate (trade name Timoptol, Rismon et al.) Which is a β blocker It is eye drops. Eye drop once a day, twice a day.
Glaucoma is a disease in which the optic nerve is damaged due to elevated intraocular pressure, the visual field gradually lacks, and there is a danger of blindness if left untreated. In Japan, one in twenty people over the age of 40 has developed, and it is the number one cause of visual impairment. Among glaucoma, there are many untreated diseased patients because there are also many types (intraocular pressure glaucoma) that the intraocular pressure does not rise, so early detection and early treatment are said to be important.
The only established treatment for glaucoma disease and ocular hypertension is to lower intraocular pressure, and as a therapeutic agent to be used, a pro
Among glaucoma patients, it is difficult to control intraocular pressure for a long time with only one eye drop, and there are many examples using two drugs in combination. However, when two or more eye drops are to be used in combination, it is necessary to open the interval between eye drops as the drug solution overflows from the lacrimal pouch when the eye drops are used successively, which causes a forgetting to drop eye drops etc. , Compliance reduction occurred, which was a problem.
The Azorga-containing suspending ophthalmic solution suppresses aqueous humor production and reduces intraocular pressure by the carbonic anhydrase inhibitor and beta blocker compounded. Because it is a combination drug, it can be applied only once to two kinds of medicine, improvement of compliance can be expected, and patient convenience is high.
Four formulations have been released as compound eye drops to be used in the treatment of glaucoma and ocular hypertension. Three of them are preparations containing prostaglandin derivative and beta blocker (timolol maleate), and the other formulation is dorzolamide hydrochloride of carbonic anhydrase inhibitor, timolol maleate of beta blocker and "Cosopto" is blended. Azorga will be a combination eye drop of a carbonic anhydrase inhibitor and a beta blocker, the second following cosoth.
The combined effects of these two agents with different mechanisms of action have been confirmed by multiple clinical trials both in Japan and abroad. Overseas, since approval in Europe (EU) in 2008, as of May 2013, it has been approved in more than 100 countries and regions.
In drug use, some side effects are recognized in 10.6% in the domestic phase III trial, so it is necessary to pay sufficient attention. The main side effects are eye irritation (3.5%), punctate keratitis (3.2%), dysgeusia (1.4%) and the like, and serious side effects include ocular pemphigus, bronchial asthma, dyspnea, respiratory failure , Heart block, congestive heart failure, cerebral ischemia, cardiac arrest, cerebrovascular accident, systemic lupus erythematosus.
|
